Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore effective ways to maximize your income for loan repayment. Enhance your finances and tackle your loans with confidence.
14,787 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Hyperliquid’s hip-3 markets surge has pushed HIP-3’s share of perpetual futures volume to roughly half, signaling a d...
Starlink’s rumored mobile service could shake up how Americans connect on the go. This guide breaks down what that me...
A simple, inexpensive way to own a broad slice of the U.S. stock market is often called a 'vanguard great investment'...
As the AI rally continues, XNTK’s 35-stock equal-weight tech approach is being weighed against QQQ’s Nasdaq-100 expos...
On July 16, the stock market faced pressure as a major space-tech name announced a $1 billion convertible notes offer...
Global smartphone shipments declined 11% year-over-year in the second quarter of 2026, marking the steepest drop in 1...
As macro conditions shift toward potential rate cuts and a steeper yield curve, the equal-weight strategy could outru...
Outside money from AIPAC-backed groups totals nearly $30 million in Michigan's Senate primary, testing how much influ...
If you’re wondering whether you should uber stock before the upcoming investor update, you’re not alone. This guide b...
A booming demand backdrop for chips collides with sky-high spending. This piece breaks down what Taiwan Semiconductor...
XRP’s on-chain health is moving beyond price to three core metrics: payments activity, DEX throughput, and validator ...